Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 15 | 2023 | 254 | 2.720 |
Why?
|
| Ultrasonography | 15 | 2025 | 207 | 2.410 |
Why?
|
| Point-of-Care Systems | 6 | 2025 | 58 | 2.020 |
Why?
|
| Abscess | 4 | 2020 | 28 | 1.910 |
Why?
|
| Soft Tissue Infections | 3 | 2020 | 25 | 1.740 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 59 | 1.590 |
Why?
|
| Humans | 53 | 2025 | 25967 | 1.310 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2020 | 18 | 1.270 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 367 | 1.220 |
Why?
|
| Heart Arrest | 2 | 2020 | 39 | 1.220 |
Why?
|
| Shoulder Dislocation | 2 | 2022 | 110 | 1.190 |
Why?
|
| Trachea | 4 | 2025 | 39 | 1.150 |
Why?
|
| Warfarin | 3 | 2022 | 25 | 0.990 |
Why?
|
| Intubation, Intratracheal | 4 | 2025 | 87 | 0.970 |
Why?
|
| Endovascular Procedures | 1 | 2025 | 31 | 0.920 |
Why?
|
| Thrombectomy | 1 | 2025 | 31 | 0.920 |
Why?
|
| Thrombolytic Therapy | 1 | 2025 | 48 | 0.900 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 37 | 0.860 |
Why?
|
| Hyperkalemia | 2 | 2021 | 5 | 0.860 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 19 | 0.860 |
Why?
|
| Drainage | 3 | 2020 | 41 | 0.850 |
Why?
|
| Retrospective Studies | 18 | 2023 | 3358 | 0.840 |
Why?
|
| Fractures, Bone | 2 | 2022 | 73 | 0.840 |
Why?
|
| Esophagus | 3 | 2022 | 57 | 0.830 |
Why?
|
| Ventricular Fibrillation | 2 | 2020 | 13 | 0.810 |
Why?
|
| Hemorrhage | 2 | 2020 | 73 | 0.790 |
Why?
|
| Antiemetics | 1 | 2022 | 10 | 0.760 |
Why?
|
| Hypoglycemia | 2 | 2021 | 12 | 0.750 |
Why?
|
| Critical Illness | 3 | 2021 | 110 | 0.750 |
Why?
|
| Sympathomimetics | 1 | 2021 | 5 | 0.750 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2020 | 11 | 0.730 |
Why?
|
| Airway Management | 1 | 2021 | 15 | 0.730 |
Why?
|
| Emergency Medicine | 2 | 2020 | 93 | 0.730 |
Why?
|
| Ketamine | 1 | 2021 | 23 | 0.730 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 43 | 0.710 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 46 | 0.700 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 39 | 0.690 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 7 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 273 | 0.680 |
Why?
|
| Skin Diseases | 1 | 2020 | 21 | 0.680 |
Why?
|
| Phenytoin | 1 | 2020 | 5 | 0.680 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 15 | 0.680 |
Why?
|
| Bites and Stings | 1 | 2020 | 3 | 0.680 |
Why?
|
| Documentation | 1 | 2020 | 23 | 0.680 |
Why?
|
| Wound Infection | 1 | 2020 | 6 | 0.680 |
Why?
|
| Status Epilepticus | 1 | 2020 | 12 | 0.670 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 5 | 0.670 |
Why?
|
| Adult | 15 | 2025 | 7662 | 0.670 |
Why?
|
| Anticonvulsants | 1 | 2020 | 54 | 0.660 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 20 | 0.650 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 26 | 0.640 |
Why?
|
| Gonorrhea | 1 | 2019 | 5 | 0.630 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 5 | 0.620 |
Why?
|
| Male | 18 | 2023 | 14277 | 0.620 |
Why?
|
| Glucagon | 1 | 2019 | 6 | 0.620 |
Why?
|
| Aftercare | 1 | 2019 | 22 | 0.620 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 10 | 0.620 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 140 | 0.610 |
Why?
|
| Retinal Detachment | 1 | 2019 | 7 | 0.610 |
Why?
|
| Pulmonary Edema | 3 | 2023 | 22 | 0.610 |
Why?
|
| Foreign Bodies | 1 | 2019 | 24 | 0.600 |
Why?
|
| Epistaxis | 1 | 2018 | 9 | 0.600 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 17 | 0.590 |
Why?
|
| Spinal Puncture | 1 | 2018 | 23 | 0.590 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 17 | 0.590 |
Why?
|
| Skin Diseases, Infectious | 1 | 2018 | 6 | 0.570 |
Why?
|
| Anthrax | 1 | 2017 | 1 | 0.570 |
Why?
|
| Transportation of Patients | 1 | 2017 | 4 | 0.560 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 3 | 0.560 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 65 | 0.560 |
Why?
|
| Female | 17 | 2023 | 14734 | 0.560 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 5 | 0.560 |
Why?
|
| Health Resources | 1 | 2017 | 22 | 0.560 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 28 | 0.550 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 32 | 0.550 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 311 | 0.550 |
Why?
|
| Anticoagulants | 3 | 2022 | 85 | 0.490 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 473 | 0.490 |
Why?
|
| Middle Aged | 13 | 2023 | 8772 | 0.480 |
Why?
|
| Azoles | 1 | 2014 | 1 | 0.450 |
Why?
|
| Tacrolimus | 1 | 2014 | 14 | 0.450 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.440 |
Why?
|
| Antifungal Agents | 1 | 2014 | 40 | 0.430 |
Why?
|
| Treatment Failure | 3 | 2020 | 152 | 0.430 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 115 | 0.410 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 98 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 106 | 0.400 |
Why?
|
| Algorithms | 1 | 2014 | 345 | 0.370 |
Why?
|
| Prospective Studies | 5 | 2023 | 1701 | 0.360 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3399 | 0.360 |
Why?
|
| Aged | 9 | 2025 | 8732 | 0.360 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2021 | 8 | 0.360 |
Why?
|
| Metoprolol | 3 | 2020 | 5 | 0.360 |
Why?
|
| Diltiazem | 3 | 2020 | 7 | 0.350 |
Why?
|
| Pharmacists | 2 | 2021 | 16 | 0.350 |
Why?
|
| Intestinal Obstruction | 2 | 2023 | 11 | 0.340 |
Why?
|
| Intensive Care Units | 3 | 2021 | 248 | 0.330 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 27 | 0.310 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 113 | 0.310 |
Why?
|
| Insulin | 2 | 2021 | 84 | 0.310 |
Why?
|
| Heart Failure | 2 | 2018 | 144 | 0.260 |
Why?
|
| International Normalized Ratio | 3 | 2022 | 18 | 0.250 |
Why?
|
| Nausea | 2 | 2023 | 24 | 0.250 |
Why?
|
| Vomiting | 2 | 2023 | 18 | 0.240 |
Why?
|
| Chicago | 2 | 2019 | 898 | 0.240 |
Why?
|
| Child | 2 | 2020 | 1217 | 0.240 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 27 | 0.240 |
Why?
|
| Bias | 1 | 2025 | 29 | 0.230 |
Why?
|
| Intracranial Hemorrhages | 1 | 2025 | 13 | 0.230 |
Why?
|
| Diverticulitis | 1 | 2025 | 6 | 0.230 |
Why?
|
| Nasal Cavity | 2 | 2021 | 32 | 0.220 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 3 | 0.210 |
Why?
|
| Potassium | 2 | 2021 | 60 | 0.210 |
Why?
|
| Dizziness | 1 | 2023 | 17 | 0.210 |
Why?
|
| Vancomycin | 2 | 2021 | 52 | 0.210 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 165 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2021 | 102 | 0.200 |
Why?
|
| Eye | 1 | 2022 | 6 | 0.200 |
Why?
|
| Metoclopramide | 1 | 2022 | 4 | 0.190 |
Why?
|
| Thrombosis | 2 | 2020 | 51 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 252 | 0.180 |
Why?
|
| Neuroimaging | 1 | 2022 | 120 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 11 | 0.180 |
Why?
|
| Stroke Volume | 2 | 2018 | 43 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 32 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 31 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 16 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 15 | 0.170 |
Why?
|
| Hypercalcemia | 1 | 2020 | 7 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 22 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 13 | 0.170 |
Why?
|
| Calcitonin | 1 | 2020 | 14 | 0.170 |
Why?
|
| Piracetam | 1 | 2020 | 7 | 0.170 |
Why?
|
| Diphosphonates | 1 | 2020 | 15 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2020 | 45 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 20 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Dogs | 1 | 2020 | 151 | 0.170 |
Why?
|
| Cellulitis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Young Adult | 2 | 2017 | 1941 | 0.160 |
Why?
|
| Seizures | 1 | 2020 | 68 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 58 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2020 | 184 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2019 | 3 | 0.160 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 170 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 224 | 0.160 |
Why?
|
| Shock | 1 | 2019 | 8 | 0.160 |
Why?
|
| Midodrine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Bezoars | 1 | 2019 | 2 | 0.160 |
Why?
|
| Peristalsis | 1 | 2019 | 11 | 0.160 |
Why?
|
| Physical Examination | 1 | 2020 | 117 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 157 | 0.160 |
Why?
|
| Manipulation, Orthopedic | 1 | 2019 | 9 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2019 | 68 | 0.150 |
Why?
|
| Administration, Topical | 1 | 2018 | 14 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 210 | 0.150 |
Why?
|
| Sepsis | 1 | 2020 | 113 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 337 | 0.150 |
Why?
|
| Capnography | 1 | 2018 | 8 | 0.150 |
Why?
|
| Lung | 3 | 2023 | 157 | 0.140 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bioterrorism | 1 | 2017 | 3 | 0.140 |
Why?
|
| Ciprofloxacin | 1 | 2017 | 11 | 0.140 |
Why?
|
| Disaster Planning | 1 | 2017 | 7 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 13 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 1391 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 16 | 0.140 |
Why?
|
| Bandages | 1 | 2017 | 4 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 230 | 0.140 |
Why?
|
| Length of Stay | 1 | 2019 | 307 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2017 | 31 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2018 | 268 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 297 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 235 | 0.130 |
Why?
|
| Infant | 1 | 2018 | 495 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2018 | 476 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2018 | 597 | 0.120 |
Why?
|
| Voriconazole | 1 | 2014 | 10 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 6 | 0.110 |
Why?
|
| Fluconazole | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 20 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 19 | 0.110 |
Why?
|
| Triazoles | 1 | 2014 | 29 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 1806 | 0.110 |
Why?
|
| Animals | 1 | 2020 | 3503 | 0.100 |
Why?
|
| Adolescent | 1 | 2017 | 2099 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 40 | 0.090 |
Why?
|
| Acute Disease | 2 | 2025 | 175 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 649 | 0.090 |
Why?
|
| Professional Role | 2 | 2021 | 28 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4641 | 0.090 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 23 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 328 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 729 | 0.060 |
Why?
|
| Vertigo | 1 | 2023 | 7 | 0.050 |
Why?
|
| Pleura | 1 | 2023 | 8 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 24 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2025 | 207 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 106 | 0.040 |
Why?
|
| Linezolid | 1 | 2021 | 4 | 0.040 |
Why?
|
| Cadaver | 1 | 2022 | 372 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 105 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 147 | 0.040 |
Why?
|
| Medical Records | 1 | 2020 | 31 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 57 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 113 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 110 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 160 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 211 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 25 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 391 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 301 | 0.040 |
Why?
|